You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Roche withdraws US indication for Tecentriq in bladder cancer

Swiss pharma company Roche has announced that it will withdraw the US indication for Tecentriq in prior-platinum treated metastatic urothelial carcinoma (mUC, bladder cancer).